Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
9461
Table 1_Promotion of physical activity-related health competence using digital workplace-based health promotion: a pilot study for office workers.docx
Published 2025“…The other sub-competences also increased, but not significantly. HEPA decreased after the intervention and at follow-up, but the decrease was not statistically significant.…”
-
9462
Image 2_Clinical outcomes of an intelligent pressure-controlled disposable ureteroscope for Laser lithotripsy in renal stone surgery: a retrospective matched cohort study.tif
Published 2025“…The overall complication rate was significantly lower in the experimental group</p>Conclusions<p>The use of an intelligent pressure-controlled disposable ureteroscope with laser lithotripsy for upper urinary tract surgeries can effectively reduce postoperative inflammation indicators, decrease average hospital stay and renal pelvis pressure, and improve the initial and total stone clearance rates.…”
-
9463
Data Sheet 2_Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.csv
Published 2025“…Additionally, we identified an increase in the ARGORNPROST-PWY pathway (L-arginine degradation, q = 0.003) and a decrease in the PWY-6478 pathway (GDP-D-glycero-α-D-manno-heptose biosynthesis, q = 0.015) in MSA patients compared with HCs.…”
-
9464
Data Sheet 3_Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.csv
Published 2025“…Additionally, we identified an increase in the ARGORNPROST-PWY pathway (L-arginine degradation, q = 0.003) and a decrease in the PWY-6478 pathway (GDP-D-glycero-α-D-manno-heptose biosynthesis, q = 0.015) in MSA patients compared with HCs.…”
-
9465
Data Sheet 4_Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.csv
Published 2025“…Additionally, we identified an increase in the ARGORNPROST-PWY pathway (L-arginine degradation, q = 0.003) and a decrease in the PWY-6478 pathway (GDP-D-glycero-α-D-manno-heptose biosynthesis, q = 0.015) in MSA patients compared with HCs.…”
-
9466
Data Sheet 1_Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.pdf
Published 2025“…Additionally, we identified an increase in the ARGORNPROST-PWY pathway (L-arginine degradation, q = 0.003) and a decrease in the PWY-6478 pathway (GDP-D-glycero-α-D-manno-heptose biosynthesis, q = 0.015) in MSA patients compared with HCs.…”
-
9467
Data Sheet 1_Global, regional, and national burden of pneumococcal disease among children and adolescents aged <20 years from 1990 to 2021: a predictive analysis.docx
Published 2025“…Despite a global decrease in burden, significant regional and socioeconomic disparities, as well as long-term trends, are not fully understood.…”
-
9468
Supplementary Material for: Longer term outcomes of laparoscopic peritoneal lavage in the management of acute Hinchey III perforated diverticulitis: A Systematic review and Meta-An...
Published 2024“…There was significantly decreased likelihood of having a stoma in the LPL group however there was also a significantly increased likelihood of having recurrent diverticulitis. …”
-
9469
Supplementary Material for: The effectiveness of Long-Term Continuation of Atezolizumab Plus Bevacizumab In Patients Who Receiving Systemic Chemotherapy For Advanced Hepatocellular...
Published 2025“…Results: According to the periods from the initiation of Atez/Bev to that of the second-line therapy, patients were classified into a long continuation group (Group-L, n = 19), ≥ 11 months; or a short continuation group (Group-S, n = 19), < 11 months. …”
-
9470
Variability of gait features during adaptation.
Published 2025“…<p>A) We observed significant differences between groups in step length asymmetry variability during EA. …”
-
9471
Table 3_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.docx
Published 2025“…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”
-
9472
Table 2_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.xlsx
Published 2025“…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”
-
9473
Table 1_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.xlsx
Published 2025“…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”
-
9474
Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
Published 2025“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
-
9475
Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
Published 2025“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
-
9476
Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
Published 2025“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
-
9477
Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx
Published 2025“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
-
9478
Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
Published 2025“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
-
9479
Data Sheet 1_Dupilumab treatment has no effect on the nasal microbiome in patients with NSAID-exacerbated respiratory disease: a longitudinal pilot study.pdf
Published 2025“…All 8 patients showed significant reduction in TPS (total polyp score; p=0.0078) and an improvement in SNOT-22 (Sino-nasal outcome test-22, a quality of life questionnaire; p=0.0781) after dupilumab therapy. …”
-
9480
Data Sheet 1_Inflammation mediated brain damage and cytokine expression in a maternally derived murine model for preterm hypoxic-ischemic encephalopathy.pdf
Published 2025“…MAP2 expression was significantly decreased (p < 0.05) between 1.5–6.0 mm of the brain compared to Saline-Hypoxia and Naïve animals. …”